Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

Bynes has been vocal about her weight-loss journey, which began in June with the trendy GLP-1 agonist drug Ozempic so she ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...